Ryght AI is building what it calls the world’s first “agentic AI platform” for clinical trials. The company’s system automates site selection, feasibility, budgeting, patient pre-screening, and even protocol authoring, areas that currently bog down timelines and strain sponsors, CROs, and research sites.
Over the past five years, AI has supercharged drug discovery. Algorithms now routinely identify new compounds, predict protein folding, and simulate early-stage efficacy, all in silico. Billions of dollars have poured into AI drug startups like Insitro, Xaira, and Genesis, promising faster, cheaper, and more precise development of new therapies.
Read more on AIJournal.com
Ryght AI, a leading provider of real-time generative AI solutions for the clinical research industry, today announced the launch of RyghtSites.com....
By integrating Ryght AI's technology, Biorasi can provide their clients with real-time, site-specific data that leads to more intelligent site...
Ryght's distinguished board of scientific experts will guide the company's research initiatives and strategic direction as it transforms clinical...